Abstract: Disclosed in the present invention are an antibody targeting LAG-3, a preparation method therefor and the use thereof. In particular, disclosed in the present invention is a novel monoclonal antibody targeting LAG-3. Also disclosed in the present invention is a method for the preparation of the monoclonal antibody. The monoclonal antibody of the present invention is capable of binding LAG-3 antigens with high specificity, and has very high affinity and significant activities such as anti-tumor activity.

Abstract: The present invention provides a humanized anti-TPBG antibody, a preparation method therefor, a conjugate thereof, and applications. The humanized anti-TPBG antibody comprises: (a), a framework region comprising a residue of a human antibody framework region; and (b) one or more CDRs of a light-chain variable region as shown in the SEQ ID NO:4 or 8 or one or more CDRs of a heavy-chain variable region as shown in the SEQ ID NO:2 or 6.

Abstract: Provided in the present invention are a 4-1BB antibody and a preparation method and the use thereof. In particular, provided in the present invention are a 4-1BB antibody, which has high affinity to 4-1BB protein, can effectively activate the signal downstream of the 4-1BB and significantly increase expression quantities of IFN-? and IL-2 in human mixed lymphocytes or T lymphocytes, and can be used to treat cancers and autoimmune diseases.

Abstract: Provided are an antibody targeting NKG2A, a preparation method therefor and use thereof. Specifically, provided is a new mouse or humanized monoclonal antibody targeting NKG2A, and a method for preparing the monoclonal antibody. The monoclonal antibody can bind to an NKG2A antigen with high specificity, and has high affinity and significant activities such as anti-tumor activity.

Abstract: Disclosed are a GITR-targeting antibody, a preparation method therefor and the use thereof. In particular, disclosed is a novel GITR-targeting chimeric antibody or a fully humanized monoclonal antibody. Also disclosed is a method for preparing the monoclonal antibody. The monoclonal antibody of the present invention can bind to a GITR antigen with a high specificity, and has a very high affinity and a significant anti-tumor activity or the like.

Abstract: An antibody targeting CD73, a preparation method therefor and a use thereof. The provided monoclonal antibody can bind to a CD73 antigen with high specificity, and has high affinity and significant antitumor activity.

Abstract: Provided are a murine or fully human monoclonal antibody targeting SEMA4D and a preparation method therefor, wherein the antibody binds to the SEMA4D antigen and has activities such as combating tumors.

Abstract: Provided are a high-affinity full human monoclonal antibody highly specifically targeting to TIM-3 and a preparation method therefor. The monoclonal antibody has a remarkable antitumor activity, and can be used for preparing a related diagnostic reagent or a pharmaceutical composition preventing or treating diseases related to TIM-3 dysfunction.

Abstract: An antibody targeting CD47, a preparation method therefor and uses thereof. A novel mouse or human-mouse chimeric antibody targeting CD47. A method for preparing the monoclonal antibody. The monoclonal antibody of the present invention can bind CD47 antigen with high specificity, has high affinity and significant activities, such as anti-tumor activity.

Abstract: Provided are a murine or human-mouse chimeric antibody targeting OX40 and a preparation method therefor, wherein the antibody binds to the OX40 antigen and has an anti-tumor activity and other activities.

Abstract: Disclosed in the present invention are an antibody targeting IL-5, a preparation method therefor and use thereof. In particular, disclosed in the present invention is a novel murine-derived or chimeric monoclonal antibody targeting IL-5. Also disclosed in the present invention is a method for preparing said monoclonal antibody. The monoclonal antibody of the present invention is capable of binding IL-5 antigen with high specificity, has high affinity and can well alleviate a series of asthma symptoms caused by IL-5, thereby achieving the effect of treating asthma.

Abstract: A BLyS antibody, preparation method therefor and application thereof, the BLyS antibody comprising one or more of CDR1, CDR2 and CDR3 of a heavy chain variable region of the BLyS antibody, and/or one or more of CDR1, CDR2 and CDR3 of a light chain variable region of the BLyS antibody. An amino acid sequence of the antibody is shown in a sequence listing. The BLyS antibody has a high affinity, and may observably and effectively seal a BLyS protein at a protein level and a cell level, and prevent the BLyS protein from binding to a receptor. The BLyS antibody lacks a cross-reaction with homologous protein antigens such as human APRIL, and enjoys good biological activity. The BLyS antibody may inhibit the proliferation of human BLyS-induced mouse B cells and may therefore be used for preparing a drug for preventing or treating diseases associated with BLyS expression or dysfunction.

Abstract: Disclosed by the present invention are an antibody targeting CTLA-4, a preparation method therefor and a use thereof. In particular, disclosed by the present invention is a novel fully human monoclonal antibody that targets CTLA-4. Further disclosed by the present invention is a method for preparing the monoclonal antibody. The monoclonal antibody of the present invention is capable of binding a CTLA-4 antigen with high specificity, has a high affinity, remarkable anti-tumor activity, and so on.

Abstract: The present invention discloses IL-13 antibody, method of its preparation and use thereof. The IL-13 antibody comprises one or more of heavy chain CDR1, heavy chain CDR2 and heavy chain CDR3 of heavy chain variable region of the IL-13 antibody, and/or one or more of light chain CDR1, light chain CDR2, and light chain CDR3 of light chain variable region of the IL-13 antibody. The IL-13 antibody has a high affinity and can significantly inhibit the secretion of thymus activation-regulated chemokine and periostin as well as the expression of vascular cell adhesion molecule-1 induced by IL-13, it can significantly inhibit airway hyperresponsiveness in mice induced by IL-13, and therefore can be used in the preparation of drugs for preventing or treating IL-13 expression or dysfunction related diseases.

Abstract: The present invention provides a TPBG antibody, a preparation method thereof, conjugates and use thereof. The TPBG antibody comprises one or more of the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 of the heavy chain variable region of TPBG antibody, and/or one or more of the light chain CDR1, the light chain CDR2 and the light chain CDR3 of the light chain variable region of TPBG antibody, and the amino acid sequences of which are described in the present invention. The TPBG antibody is humanized antibody with high affinity, and the conjugates prepared by coupling the TPBG antibody with the small-molecule drug toxin MMAF can have a cytotoxicity effects on TPBG-positive cells, therefore the TPBG antibody can be used in the preparation of drugs for treating tumors and the like.

Abstract: This application provides a lithium-ion battery, a positive electrode plate for a lithium-ion battery, and an apparatus. The lithium-ion battery includes a positive electrode plate that includes a positive current collector and a positive active material layer arranged on at least one surface of the positive current collector. A positive active material in the positive active material layer includes a positive active substance I and a positive active substance II. The positive active substance I is a layered lithium nickel transition metal oxide. The positive active substance II is an olivine-type li-containing phosphate. The positive electrode plate satisfies 2.5?N/(PD×(1?P1)×(1?A))?21. The positive electrode plate for a lithium-ion battery has relatively high energy density, and a high transmission rate of lithium ions, which effectively increases instantaneous discharge power under a low SOC while ensuring high volume energy density of lithium-ion batteries using the positive electrode plate.

Abstract: Disclosed in the present invention are an antibody targeting LAG-3, a preparation method therefor and the use thereof. In particular, disclosed in the present invention is a novel monoclonal antibody targeting LAG-3. Also disclosed in the present invention is a method for the preparation of the monoclonal antibody. The monoclonal antibody of the present invention is capable of binding LAG-3 antigens with high specificity, and has very high affinity and significant activities such as anti-tumor activity.

Abstract: Anti-PD-1 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancers and autoimmune diseases.

Abstract: The present invention provides an anti-C5aR antibody and a preparation method and use thereof. The anti-C5aR antibody comprises one or more of the followings: a heavy chain CDR1, heavy chain CDR2 or heavy chain CDR3 of a heavy chain variable region of an anti-C5aR antibody, and one or more of the followings: a light chain CDR1, light chain CDR2 or light chain CDR3 of a light chain variable region of the anti-C5aR antibody. The anti-C5aR antibody has a high affinity to human C5aR protein and can block the binding of the C5aR protein to a C5a, thus downregulating or switching off a corresponding signaling pathway, stopping C5a directed migration of a neutrophil in vitro and inhibiting chemotaxis of the neutrophil.

Abstract: Disclosed are an EGFRvIII antibody and a conjugate, and a preparation method and the use thereof. The antibody comprises complementarity-determining regions (CDRs) of the EGFRvIII antibody: one or more of heavy chain CDR1, heavy chain CDR2 and heavy chain CDR3, and/or one or more of light chain CDR1, light chain CDR2 and light chain CDR3, with the amino acid sequence thereof being as described in the present invention. The EGFRvIII antibody has a high affinity with the EGFRvIII protein, and can enter cells after coupling with small molecule toxins such as MMAE and has a cytotoxic killing effect on EGFRvIII positive cells. The antibody therefore can be used for preparing drugs for treating tumors and other diseases.